Annals of Oncology – ESMO Abstract 233P

Link to PDF (annalsofoncology.org) 233P – Breast Cancer Organoids Mimic Disease Heterogeneity, Allow High-Throughput Drug Screening and Show Correlation with Clinical Response Abstract 233P Background Breast cancer (BC) is a highly heterogeneous disease; therefore, it is urgent to identify an ex vivo model that accurately mimics the heterogeneity. Patient-derived organoids (PDOs) represent an ideal preclinical model …

Read more

ESMO Breast Cancer 2022, Berlin, Germany

Invitrocue Chief Scientific Officer, Dr. Zahra Dantes, will be presenting our latest findings on our current validation study regarding breast cancer at ESMO Breast Cancer 2022, 3-5 May, in Berlin. “Breast Cancer Organoids Mimic Disease Heterogeneity, Allow High-Throughput Drug Screening, and Show Correlation with Clinical Response” #202, Wednesday, 4 May, from 12:15 to 13:00 CEST. …

Read more

Webinar – New Trends in Drug Discovery : Robotics and AI

The drug discovery ecosystem is changing rapidly. The rise of robotics and AI enables the emergence of a new model of data-driven drug discovery. Bringing together recent advances in life sciences automation and machine learning applications for drug discovery, new partnerships evolve that allow for game-changing improvements in the drug discovery process. The webinar will …

Read more

Invitrocue Establishes Hong Kong Laboratory

Invitrocue Establishes Hong Kong Laboratory Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce the establishment of laboratory facility in Hong Kong. The Hong Kong facility, which will be used for research and development and for commercial purposes, provides Invitrocue with better access to the network of supportive …

Read more

Invitrocue Clinical Studies underway in Germany

Invitrocue Clinical Studies underway in Germany Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce that a clinical validation study is underway for its Onco-PDO test with Klinikum Rechts der Isar der Technischen Universitat Munchen, Comprehensive Cancer Center Munich, Germany.

Collaboration with National University Hospital Singapore

Collaboration with National University Hospital Singapore 08 August, 2019: Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the commencement of a clinical validation collaboration with National University Hospital (NUH), a leading public teaching hospital in Singapore. The aim of the clinical study is to validate Invitrocue’s Onco-PDO drug screening …

Read more

Invitrocue Appoints Global Insurance Advisor

IVQ Appoints Global Insurance Advisor 06 May, 2019: Innovative life sciences company Invitrocue Limited (ASX: IVQ), (‘Invitrocue’ or ‘the Company’), is please to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor. In his role at Invitrocue, Dato Dr Wahab will advise and support the Company’s global insurance strategy for its Onco …

Read more

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

EXCERPT:  February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an …

Read more

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

EXCERPT:  February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system …

Read more